Insider trades
Mark Lappe, CEO of Inhibrx Biosciences INBX, has filed 15 purchases and 4 sales on the open market. Over the past 12 months that comes to a net purchase of $998.8K. The latest trade was on 09/28.
Mark Lappe
CEO
- Company
- Inhibrx Biosciences INBX
- First filing
- 23/03/01
- Trades
- 29 trades
- Buys / sales
- 15 / 4
- 12-month net buying
- $998.8K
- Last trade
- 09/28
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
INBX | Open-market buy | 09/25–09/28 | 09/28 | 10,000 sh4 trades | $99.88avg. | $998,783.69 | +1.4% |
INBX | Open-market buy | 24/09/12–24/09/16 | 24/09/16 | 40,000 sh2 trades | $15.73avg. | $629,116.96 | +6.0% |
INBX | Open-market buy | 24/09/06–24/09/10 | 24/09/10 | 44,000 sh3 trades | $15.25avg. | $671,150 | +7.1% |
INBX | Open-market buy | 24/08/29–24/09/03 | 24/09/03 | 40,000 sh4 trades | $14.92avg. | $596,762.8 | +32.0% |
INBX | Open-market buy | 24/08/20–24/08/21 | 24/08/22 | 40,000 sh2 trades | $12.96avg. | $518,282.2 | +269.1% |
| Open-market sale | 23/02/28 | 23/03/01 | 60 sh | $25.02 | $1,501.2 | −0.0% | |
| Open-market sale | 23/01/23–23/01/24 | 23/01/24 | 26,000 sh3 trades | $25.42avg. | $660,902.45 | −1.0% |